Suzetrigine: A novel selective sodium channel inhibitor for pain
American Journal of Health-System Pharmacy · 09.03.2026 · 83 (6) · 245-253
DOI: 10.1093/ajhp/zxaf219 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 18.08.2025. Verfasst von Denise Courtney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Health Administration Southeast Network, Decatur, GA, USA. Hauptthemen laut MEDLINE: Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers, Pain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Purpose
To explore suzetrigine, a novel voltage-gated sodium channel inhibitor for pain management. Summary Suzetrigine is a first-in-class, oral peripheral sodium channel inhibitor that selectively targets Nav1.8 channels and was recently approved for the treatment of moderate to severe acute pain. In phase 3 trials, suzetrigine demonstrated superior efficacy to placebo in reducing pain intensity after surgery and was generally well tolerated. Studies for nonacute pain indications, including diabetic peripheral neuropathy and painful lumbosacral radiculopathy, are in progress.
Conclusion
Suzetrigine represents an advancement in pain management as a nonopioid alternative for pain with potentially lower abuse risk and potentially fewer serious adverse effects when compared to opioids. While initial results are promising, further research is needed to establish its long-term safety and efficacy for various painful conditions. Research will continue in the area of analgesics that selectivity inhibit peripheral sodium channels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Veterans Health Administration Southeast Network, Decatur, GA, USA.
- Atlanta VA Health Care System, Decatur, GA, USA.
- VA Capitol Health Care Network, Washington, DC, USA.
Zitieren
APA
Courtney, D., Potru, S., & Mathew, P. (2026). Suzetrigine: A novel selective sodium channel inhibitor for pain. American Journal of Health-System Pharmacy, 83(6), 245-253. https://doi.org/10.1093/ajhp/zxaf219
Vancouver
Courtney D, Potru S, Mathew P. Suzetrigine: A novel selective sodium channel inhibitor for pain. American Journal of Health-System Pharmacy. 2026;83(6):245-253. doi:10.1093/ajhp/zxaf219
BibTeX
@article{Courtney2026,
author = {Courtney, Denise and Potru, Sudheer and Mathew, Paige},
title = {Suzetrigine: A novel selective sodium channel inhibitor for pain},
journal = {American Journal of Health-System Pharmacy},
year = {2026},
volume = {83},
number = {6},
pages = {245--253},
doi = {10.1093/ajhp/zxaf219}
}
EUVIMED